Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Oncologist. 2019 Dec;24(12):e1401-e1408. doi: 10.1634/theoncologist.2018-0587. Epub 2019 Jun 11.
Tumor mutational burden (TMB) measured via next-generation sequencing (NGS)-based gene panel is a promising biomarker for response to immune checkpoint inhibitors (ICIs) in solid tumors. However, little is known about the preanalytical factors that can affect the TMB score.
Data of 199 patients with solid tumors who underwent multiplex NGS gene panel (OncoPrime), which was commercially provided by a Clinical Laboratory Improvement Amendments-licensed laboratory and covered 0.78 megabase (Mb) of capture size relevant to the TMB calculation, were reviewed. Associations between the TMB score and preanalytical factors, including sample DNA quality, sample type, sampling site, and storage period, were analyzed. Clinical outcomes of patients with a high TMB score (≥10 mutations per megabase) who received anti-programmed cell death protein 1 antibodies ( = 22) were also analyzed.
Low DNA library concentration (<5 nM), formalin-fixed paraffin-embedded tissue (FFPE), and the prolonged sample storage period (range, 0.9-58.1 months) correlated with a higher TMB score. After excluding low DNA library samples from the analysis, FFPE samples, but not the sample storage period, exhibited a marked correlation with a high TMB score. Of 22 patients with a high TMB score, we observed the partial response in 2 patients (9.1%).
Our results indicate that the TMB score estimated via NGS-based gene panel could be affected by the DNA library concentration and sample type. These factors could potentially increase the false-positive and/or artifactual variant calls. As each gene panel has its own pipeline for variant calling, it is unknown whether these factors have a significant effect in other platforms.
A high tumor mutational burden score, as estimated via next-generation sequencing-based gene panel testing, should be carefully interpreted as it could be affected by the DNA library concentration and sample type.
通过下一代测序(NGS)基因面板测量的肿瘤突变负担(TMB)是实体瘤对免疫检查点抑制剂(ICI)反应的有前途的生物标志物。然而,对于可能影响 TMB 评分的分析前因素知之甚少。
回顾了 199 名接受多重 NGS 基因面板(OncoPrime)检测的实体瘤患者的数据。该基因面板由经过临床实验室改进修正案(CLIA)许可的实验室商业化提供,覆盖了与 TMB 计算相关的 0.78 兆碱基(Mb)的捕获大小。分析了 TMB 评分与分析前因素(包括样本 DNA 质量、样本类型、采样部位和储存期)之间的相关性。还分析了接受抗程序性细胞死亡蛋白 1 抗体治疗的 TMB 评分较高(≥10 个突变/兆碱基)患者的临床结果(n = 22)。
低 DNA 文库浓度(<5 nM)、福尔马林固定石蜡包埋组织(FFPE)和样本储存时间延长(范围 0.9-58.1 个月)与 TMB 评分较高相关。在从分析中排除低 DNA 文库样本后,FFPE 样本而非样本储存时间与 TMB 评分显著相关。在 22 名 TMB 评分较高的患者中,我们观察到 2 名患者(9.1%)出现部分缓解。
我们的结果表明,通过 NGS 基因面板估计的 TMB 评分可能受到 DNA 文库浓度和样本类型的影响。这些因素可能会增加假阳性和/或人为变异的检出率。由于每个基因面板都有自己的变异检出管道,尚不清楚这些因素在其他平台上是否有显著影响。
通过下一代测序基因面板检测估计的高肿瘤突变负担评分应谨慎解释,因为它可能受到 DNA 文库浓度和样本类型的影响。